Related Experiment Video
Updated: Sep 8, 2025

09:33
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
Enriched Environment Alleviate AD Pathological Progression by Reducing Microglia Complement Signaling in Aged Male
Hai-Chao Chen1, Jia-Xin Cao1, Yi-Shu Zhang1
1Institute of Anatomy and Histology & Embryology, Neuroscience, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
Summary
Enriched environments improve memory and reduce Alzheimer's disease (AD) pathology in mice by decreasing inflammation and preserving neuronal connections. This suggests environmental enrichment can slow AD progression.
Area of Science:
- Neuroscience
- Gerontology
- Pathology
Background:
- Alzheimer's disease (AD) involves genetic and environmental factors.
- Previous research indicates enriched environments benefit AD mice, but mechanisms are unclear.
Purpose of the Study:
- Investigate enriched environment effects on AD pathology and cognition in aged APP/PS1 mice.
- Elucidate mechanisms by which enriched environments impact Alzheimer's disease progression.
Main Methods:
- Utilized aged APP/PS1 transgenic mice and wild-type littermates.
- Subjected mice to standard (SE) or enriched (EE) environments for 5 months.
- Assessed cognitive function, amyloid-beta (Aβ) and phosphorylated-tau (p-Tau) aggregation, microglial inflammation markers (Tlr-4, NF-κB, iNOS), C1q expression, and dendritic spine integrity.
Main Results:
- Enriched environments preserved cognitive function in APP/PS1 mice.
- EE reduced Aβ and p-Tau aggregation, and microglial inflammation.
- EE decreased C1q expression and slowed dendritic spine loss in the hippocampus.
Conclusions:
- Enriched environments can mitigate Alzheimer's disease progression.
- Mechanisms include regulating microglial inflammation and maintaining neuronal integrity, particularly hippocampal dendritic spines.
Related Concept Videos
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260

